Nishino Shogo, Yunokawa Mayu, Matsuura Yosuke, Fusegi Atsushi, Misaka Satoki, Aoki Yoichi, Abe Akiko, Omi Makiko, Kanao Hiroyuki
Department of Gynecologic Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550 Japan.
Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550 Japan.
Int Cancer Conf J. 2024 Sep 5;13(4):395-400. doi: 10.1007/s13691-024-00696-0. eCollection 2024 Oct.
Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.
贝伐单抗所致的继发性自发性气胸（SSP）在其他恶性肿瘤中已有报道，但在宫颈癌中尚未见报道。我们报告了一例57岁III B期宫颈癌女性患者，在接受贝伐单抗化疗期间发生了SSP。尽管基于顺铂的放化疗实现了完全缓解，但9个月后她出现了复发。进行了胸腔镜手术以切除肺结节和肺大疱。随后，发现宫颈局部病变复发并出现肺转移，遂给予紫杉醇、卡铂联合贝伐单抗治疗。两个周期后，出现1级左侧气胸，归因于贝伐单抗引起的组织脆弱性。经保守治疗，患者在7天内病情好转。停用贝伐单抗后，气胸未再复发。该病例凸显了接受贝伐单抗治疗的宫颈癌患者中SSP的罕见发生情况，并强调了对此类患者进行适当管理的重要性，尤其是那些接受过早期胸外科手术的患者。
